A central role of plasmin in cardiac injury initiated by fetal exposure to maternal anti-Ro autoantibodies

Rheumatology (Oxford). 2013 Aug;52(8):1448-53. doi: 10.1093/rheumatology/ket156. Epub 2013 Apr 18.

Abstract

Objective: Cardiac neonatal lupus (cardiac-NL), initiated by surface binding of anti-Ro60 autoantibodies to apoptotic cardiocytes during development, activates the urokinase plasminogen activator/urokinase plasminogen activator receptor (uPA/uPAR) system. Subsequent accumulation of apoptotic cells and plasmin generation facilitates increased binding of anti-Ro60 by disrupting and cleaving circulating β2-glycoprotein I (β2GPI) thereby eliminating its protective effect. The association of soluble levels of components of the uPA/uPAR system with cardiac-NL was examined.

Methods: Levels of the uPA/uPAR system were assessed by ELISA in cord blood and immunohistological evaluation of autopsies.

Results: uPA, uPAR and plasminogen levels were each significantly higher in cord blood from cardiac-NL (n = 35) compared with non-cardiac-NL (n = 26) anti-Ro-exposed neonates: 3.3 ± 0.1 vs 1.9 ± 0.05 ng/ml (P < 0.0001), 6.6 ± 0.3 vs 2.1 ± 0.2 ng/ml (P < 0.0001) and 435 ± 34 vs 220 ± 19 ng/ml (P < 0.0001), respectively. In three twin pairs discordant for cardiac-NL, the twin with cardiac-NL had higher levels of uPA, uPAR and plasminogen than the unaffected twin (3.1 ± 0.1 vs 1.9 ± 0.05 ng/ml; P = 0.0086, 6.2 ± 1.4 vs 2.2 ± 0.7 ng/ml; P = 0.147 and 412 ± 61 vs 260 ± 27 ng/ml; P = 0.152, respectively). Immunohistological evaluation of three hearts from fetuses dying with cardiac-NL revealed macrophages and giant cells expressing uPA and plasminogen in the septal region.

Conclusion: Increased soluble uPA, uPAR and plasminogen in cord blood and expression in affected tissue of fetuses with cardiac-NL supports the hypothesis that fetal cardiac injury is in part mediated by plasmin generation initiated by anti-Ro binding to the apoptotic cardiocyte.

Keywords: apoptosis; fibrosis; inflammation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Antinuclear / immunology
  • Antibodies, Antinuclear / metabolism
  • Biomarkers
  • Case-Control Studies
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Fetal Blood / immunology*
  • Fibrinolysin / immunology*
  • Fibrinolysin / metabolism
  • Heart Diseases / immunology*
  • Heart Diseases / mortality
  • Heart Diseases / pathology
  • Humans
  • Immunohistochemistry
  • Infant, Newborn
  • Lupus Erythematosus, Systemic / congenital*
  • Lupus Erythematosus, Systemic / immunology
  • Lupus Erythematosus, Systemic / mortality
  • Lupus Erythematosus, Systemic / pathology
  • Macrophages / immunology
  • Myocytes, Cardiac / immunology
  • Myocytes, Cardiac / metabolism
  • Pregnancy
  • Receptors, Urokinase Plasminogen Activator / blood
  • Receptors, Urokinase Plasminogen Activator / immunology*
  • Reference Values
  • Ribonucleoproteins / immunology*
  • Ribonucleoproteins / metabolism
  • Survival Rate
  • Urokinase-Type Plasminogen Activator / blood
  • Urokinase-Type Plasminogen Activator / immunology

Substances

  • Antibodies, Antinuclear
  • Biomarkers
  • Receptors, Urokinase Plasminogen Activator
  • Ribonucleoproteins
  • SS-A antibodies
  • SS-A antigen
  • Fibrinolysin
  • Urokinase-Type Plasminogen Activator

Supplementary concepts

  • Neonatal Systemic lupus erythematosus